Amgen heads into Q1 earnings with growth from key drugs offset by pricing pressure, patent losses, and biosimilar competition.

Evaluate the expected performance of Amgen (AMGN) for the quarter ended March 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for ...

TrumpRx has signed deals with 86% of the branded drug market. But are prices actually falling for most Americans? A doctor ...

The MarketWatch News Department was not involved in the creation of this content. MISSISSAUGA, ON, April 7, 2026 /CNW/ - Amgen Canada announced today that the Governments of Ontario and Quebec have ...

Nasdaq 100, S&P 500, Dow Jones Industrial Average, Microsoft Corporation. Read 's Market Analysis on Investing.com ...

While prominent physicians can provide companies with valuable guidance during development, their perspective is limited when ...

Cardiovascular care is transitioning from primarily managing acute conditions to focusing on prevention and interventions for ...

Delve into the pipeline strategy of major biotech Amgen, which is increasingly diversifying its growth engines.

It’s been a little over two months since President Donald Trump’s direct-to-consumer pharmaceutical site, TrumpRx, launched, ...

Investing.com - Cantor Fitzgerald maintained a Neutral rating on Amgen Inc. (NASDAQ:AMGN) stock with a $350.00 price target on Tuesday. The stock currently trades at a P/E ratio of 23.85 with a ...

In the early 1960s, Norwegian physician Kåre Berg, M.D., was trying to identify new blood types when he accidentally discovered a lipoprotein with perplexing properties. Similar to cholesterol, but ...

Over the past several days, two major developments have emerged in the world of cholesterol-lowering therapies—specifically concerning the heavy-hitters known as PCSK9 inhibitors. In this letter, I’d ...